The Melanoma Content Hub Channel

T-Cell Therapies Spark Interest in Melanoma, Despite Clinical Challenges

Interest

Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center within the Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center Hillman Cancer Center, discussed the future of T-cell therapies in melanoma, emerging biomarkers, and ongoing research regarding the gut microbiome, in an extended interview.

Learn more by clicking here.

More in Melanoma Content Hub

►

Chipping Away at the Surface of Melanoma Treatment: Narrowing Down Therapies

Melanoma Content Hub

Rahul Seth, DO, assistant professor of medicine at Upstate University Hospital, provides recommendations for the treatment of melanoma. For patients with unresectable melanoma, Dr. Seth recommends a combination of nivolumab...

► 1:45

Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases

Melanoma Content Hub

Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses...

►

Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure

Melanoma Content Hub

Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition. FMT patients...

►

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Melanoma Content Hub

Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the assessment of...